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abstract
PURPOSE To improve outcomes for lung cancer through low-dose computed tomography (LDCT) early lung
cancer detection. The International Association for the Study of Lung Cancer is developing the Early Lung
Imaging Confederation (ELIC) to serve as an open-source, international, universally accessible environment to
analyze large collections of quality-controlled LDCT images and associated biomedical data for research and
routine screening care.
METHODS ELIC is an international confederation that allows access to efficiently analyze large numbers of high-
quality computed tomography (CT) images with associated de-identified clinical information without moving
primary imaging/clinical or imaging data from its local or regional site of origin. Rather, ELIC uses a cloud-based
infrastructure to distribute analysis tools to the local site of the stored imaging and clinical data, thereby allowing
for research and quality studies to proceed in a vendor-neutral, collaborative environment. ELIC’s hub-and-
spoke architecture will be deployed to permit analysis of CT images and associated data in a secure envi-
ronment, without any requirement to reveal the data itself (ie, privacy protecting). Identifiable data remain under
local control, so the resulting environment complies with national regulations and mitigates against privacy or
data disclosure risk.
RESULTS The goal of pilot experiments is to connect image collections of LDCT scans that can be accurately
analyzed in a fashion to support a global network using methodologies that can be readily scaled to accrued
databases of sufficient size to develop and validate robust quantitative imaging tools.
CONCLUSION This initiative can rapidly accelerate improvements to the multidisciplinary management of early,
curable lung cancer and other major thoracic diseases (eg, coronary artery disease and chronic obstructive
pulmonary disease) visualized on a screening LDCT scan. The addition of a facile, quantitative CT scanner image
quality conformance process is a unique step toward improving the reliability of clinical decision support with CT
screening worldwide.
JCO Clin Cancer Inform 4:89-99. © 2020 by American Society of Clinical Oncology
Licensed under the Creative Commons Attribution 4.0 License
INTRODUCTION
Lung cancer is the most lethal cancer throughout the
world, and it typically presents at a late stage when
cure is unlikely.1,2 Recent reports have demonstrated
the usefulness of low-dose computed tomography (CT)
screening in reducing lung cancer mortality in heavily
tobacco-exposed individuals.3-7 However, to achieve
the most efficient screening management, groups
have incorporated a quantitative assessment of pul-
monary nodule volume to guide the diagnostic
case–finding efforts within the screening process.8-12
In this fashion, the false-positive detection rate can be
reduced from 28% to approximately 3%.10-12 This
improves the screening cost and reduces the potential
for iatrogenic harm, which would be a critical aspect to
include in the global implementation of computed
tomography (CT) screening.13 The concept of de-
veloping an early lung cancer image registry emerged
through a series of workshops sponsored by the In-
ternational Association for the Study of Lung Cancer
(IASLC) as a critical opportunity to accelerate the pace
of innovation in improving the curative management
for detection and intervention with early lung cancer.
The IASLCmission is to improve lung cancer outcomes
through international and multidisciplinary collabora-
tive efforts. This large collaborative image archival
and analysis effort builds on the established IASLC
successes with the national and international lung
cancer IASLC TNM Staging Committee, which has
been undertaken in collaboration with the Union for
International Cancer Control and American Joint
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updated lung cancer pathology collaboration with the
WHO.14,15 Success in developing screening tools, as with
the staging and pathology efforts, involves issues of scale
and cost that leverage the IASLC’s broad international
scope and expertise in aligning global participation to
improve early lung cancer management.
To date, no consensus image analysis tool has emerged to
allow routine and reliable volumetric characterization of
pulmonary nodules in routine clinical imaging settings.
Developing a tool to allow easy and robust nodule mea-
surement requires access to large numbers of high-quality
thoracic CT images that were acquired with the intent of
precisely measuring volumes of pulmonary nodules 5 to
10 mm in diameter. Because this is a newly appreciated
opportunity as lung imaging technology rapidly improves,
lung images from earlier CT screening trials were generally
not acquired with sufficient resolution to enable this pre-
cise volumetric tool development. Therefore, prospective
collections of CT images from current-generation, high-
resolution CT scanners are urgently required to address
this gap. This lack of large quantities of such high-quality
image data imposes a profound barrier to progress with
early lung cancer management.
How to Bring Value to Early Lung Cancer Detection
In response to this situation, the IASLC hosted a planning
workshop held in Dallas, Texas, in February 2018. Al-
though aware of the heterogeneous nature of existing image
registries at leading centers from around the world, the
group proposed the creation of a cloud-based informatics
infrastructure to interact with existing international regis-
tries and centers collecting thoracic CT images together
with associated core clinical outcomes data to optimize cost
and data security.
This IASLC Early Lung Imaging Confederation (ELIC) was
proposed as a hub-and-spoke architecture with the in-
tention of enabling the imaging-donating local site to retain
all of the images and metadata within their defined spoke
environment consistent with local governing data-sharing
provisions. With local site permission, their stored clinical
and imaging data can be made accessible, to allow soft-
ware tools distributed to the spoke from the hub to the
relevant stored digital data. In this confederated architec-
ture, the hub acts as a conduit with the spokes to dis-
tribute software analysis tools to the relevant spokes and
then to aggregate the results of the analysis of the images
stored locally in the participating spokes. Therefore, only
the resulting analysis data will leave an individual spoke.
The resulting analysis data aggregated in the hub from
multiple sites with diverse populations allow for research
and for quality questions to be addressed with a poten-
tially vast number of test screening cases from multiple
countries.
To accommodate this architecture, the most cost-feasible
approach for a flexible, scalable, and sustainable envi-
ronment capable of enabling the goals of ELIC is to leverage
the global accessibility of a cloud environment.16 Currently,
thoracic CT screening images and associated clinical
outcomes and relevant metadata are stored in a vast array
of architectures across IASLC member sites. We envision
developing a vendor-neutral, secure, scalable, cloud-based
environment to bridge to existing sites’ data storage re-
sources. Table 1 summarizes the design considerations
guiding the development of this informatics resource. Given
the dynamic and complex nature of the privacy challenges
inherent in collecting and sharing large amounts of imaging
and clinical data, the proposed IASLC imaging/data re-
source may be preferable for many national sponsors to
have a rigorously designed, precompetitive environment
hosted by an international, nonprofit professional society
such as IASLC. IASLC has a proven legacy of patient
benefit and as a reliable host to ensure appropriate




Can an open-source cloud-based environment become a repository of screening computed tomography images and as-
sociated data to enable quantitative and related imaging tool development for use in guiding the management of early,
presymptomatic lung cancer and related thoracic diseases?
Knowledge Generated
A prototype international, open-source imaging resource is proposed that can allow federated image/data interrogation. This
construct is designed to comply with existing international standards for data security while enabling the development and
validation of new imaging biomarkers to facilitate early lung cancer management.
Relevance
Lung cancer screening is emerging as an important approach for early lung cancer management. However, robust and
economic image analysis tools are needed to ensure facile clinical workflows for pulmonary nodule detection and
quantitative nodule assessment so that this new service can be provided to the target high-risk population at high quality
throughout the world.
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High-Quality Image Acquisition
For optimal efficiency, there is also the need to pro-
spectively ensure that newly accrued thoracic CT images
are objectively of sufficiently high quality to support robust
quantitative analysis. Because ELIC is envisioned to be
a resource to develop and then validate image processing
algorithms as required to support clinical decision making
for early lung cancer management, such efforts will move
into the rapidly evolving realm of deep learning methods or
artificial intelligence approaches; therefore, the curation of
an image collection that has been optimized for quantitative
measurement is critical.17,18
Reliable guidance and clinical management in the lung
cancer screening setting requires accurate and robust
analysis of pulmonary nodule volume. Therefore, ELIC will
require image-sharing sites to prospectively adhere to the
Quantitative Imaging Biomarkers Alliance (QIBA) of the
Radiologic Society of North America (RSNA) CT Small Lung
Nodule Profile quality provisions to ensure that aggregated
imaging data obtained for quantitative analysis are of a high
quality; this is a unique strength of the ELIC effort.19,20
From extensive work in optimizing image measurement
quality in this setting, the QIBA has developed a process to
address these factors.17,18 This entails analyzing pulmonary
nodules in the volume range relevant to lung cancer
screening (6-10 mm in diameter). Crowd-sourced data
collected from international QIBA CT Small Lung Nodule
testing sites have been used over the past 2 years to help
identify and globally disseminate the top-performing CT
image acquisition protocols for each CT scanner model.
This innovative approach has enabled what we believe to
be the first rapid global optimization of scanner image
acquisition protocols for CT lung nodule measurement. The
data are also revealing new insights into low-dose CT lung
cancer screening image acquisition performance, in-
cluding the reproducibility of image acquisition properties,
differences between requested and obtained slice thick-
ness, and losses of resolution associated with lowering the
radiation dose.21
METHODS
A proof-of-concept demonstration was developed in 2018
to evaluate the potential of a hub-and-spoke–distributed
lung cancer screening image archive and computing ar-
chitecture to achieve the goals of ELIC19. Ten international
cloud computing sites were chosen from the Amazon Web
Services global cloud network map to launch and set-up
spoke EC2 cloud computing instances, as shown in Figure
1. This figure overlays the 10 ELIC spokes feeding a central
hub (at the point of the arrow) on the Amazon Web Services
global cloud network map. The hub is shown (with the blue
circle at the tip of the arrow), with each of the 10 spokes
(indicated by green circles) populated with an identical set
of 100 publicly available de-identified CT lung scans. As
shown on the map, existing AWS cloud services sites are
indicated by smaller (lighter) blue and purple circles. This
distribution of existing cloud resources demonstrate the
global reach of AWS to support local/regional hosting of
available lung cancer screening images and corresponding
clinical data as required by General Data Protection Reg-
ulations. Each of these spokes was populated with an
identical set of 100 publicly available de-identified CT lung
scans.20 However, each scan was given a unique patient ID
and fictitious age, sex, and pack-year demographics. This
was done so that proof-of-concept performance testing
could be obtained with the equivalent of 1,000 patient
cases; the analyses described in this report were repeated
on at least 5 separate occasions. In addition, a Hub EC2
cloud computing instance was set up at the Northern
Virginia location of the Amazon Web Services cloud.
Figure 2 is a schematic representation of the computing
resources and main data flows that were used during the
design of the ELIC Hub-and-Spoke Environment (H&SE)
software. A lung cancer screening principal investigator
(PI; A) typically coordinates CT lung cancer screening
for several screening sites shown as sources (Ai). The PI
is responsible for submitting de-identified lung cancer
screening image DICOM (Digital Imaging and Communi-
cations in Medicine) data and metadata, including any
requested image annotations, before data upload to a
spoke (B). Each time data on the spoke (B) are added or
corrected, a set of basic demographics and metadata in-
formation about the new data is communicated to the hub
(C). In this way, the hub and spoke will remain in agreement
regarding the data that a PI has made available for analysis
on the spoke (B). Because the spoke (B) can be set up on
a local cloud computing instance or on local computing
hardware, the spoke (B) data will remain within the source
TABLE 1. Guiding Principles of ELIC
In alignment with its mission and charge, ELIC seeks to share its resource with both
national and international scientific lung cancer research communities by:
Promoting the common good by maximizing collaborative research for the
benefit of all
Making ELIC research data available to the research community to advance
scientific knowledge
Providing open-source resources including an environment and tools to
ensure broadest dissemination of resources to enhance outcomes with
tobacco-related diseases
Ensuring the generation of high-quality research
Respecting the legal rights and legitimate interests of all stakeholders involved
Protecting the privacy of its research participants and the confidentiality of
their data
Promoting transparency, responsibility, interoperability, and fairness
Ensuring accountability and oversight
Enriching the content of the ELIC database, including through the return of
high quality–derived data by researchers
Managing access to ELIC data to balance current and future needs
Abbreviation: ELIC, Early Lung Imaging Confederation.
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geographic region and will only be analyzed according to
strictly administered analysis and reporting rules (D) de-
cided by the PI (A). The data residing on all spokes are de-
identified by the PI (A) before upload.
Thus, at all times, only de-identified data are stored on the
ELIC H&SE and, at rest, the data are also encrypted. Each
ELIC spoke contains a de-identified set of data stored on
a spoke using identical ELIC H&SE data storage organi-
zation and methods. This allows the ELIC H&SE software to
contain fully automated scripts for thoroughly performing
required data protection operations, such as the General
Data Protection Regulation “right to be forgotten.” Each
ELIC spoke will have automated scripts that achieve the
data governance protections and procedures required by
local regulations, some of which will be standard and can
be provided by the same ELIC H&SE script for all regions.
A client (E) can view a listing or catalog of all the data sets










FIG 1. The global distribution of the hub and spokes for the 2018World Conference on Lung Cancer ELIC proof-of-concept demonstrations using














































FIG 2. High-level illustration of the ELIC Hub & Spoke Environment and how lung cancer screening principal in-
vestigators (PI) and clients will interact with the system. DICOM, Digital Imaging and Communications in Medicine;
ELIC, Early Lung Imaging Confederation.
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necessary steps to run a quantitative algorithm on all the
data or on a subset of the data available within the ELIC
environment. This is referred to as running an “experiment”
within the ELIC environment. To run an experiment, the
client (E) must provide a quantitative algorithm according to
ELIC H&SE specifications to the hub (C) and request that
the hub execute the experiment on all the relevant spokes
(B). The hub (C) then coordinates the running of the
quantitative algorithm on the spokes and collects the re-
sults according to the analysis rules (D) agreed to by the PI.
When the experiment is finished, the client (E) is provided
an aggregate summary of all the data collected from the
experiment, including information on any errors or issues
encountered while running the experiment. A prototype
hub password-protected Website22 was created that dis-
plays the status of spokes, allows the specification and
launching of quantitative lung imaging experiments on
global collections of data, and provides a real-time quan-
titative and graphic display of the results obtained from the
international spoke calculations.
Two cloud-based experiments using software algorithms
were created to accept DICOM data and produce quanti-
tative results and images in a standard format that the ELIC
H&SE supports. One algorithm quantitatively measured
total lung volume, and the second algorithm quantitatively
measured the volume of solid pulmonary nodules. This
permitted the ELIC H&SE to demonstrate running the
quantitative imaging experiments on image collections
at globally distributed spokes and then aggregating the
quantitative CT image measurements and output image
results on the hub. Each of the 10 spokes was set up to run
one of the 2 quantitative CT lung image measurement
algorithms when requested by the hub.
The project also deployed the QIBA CT Small Lung Nodule
Profile Conformance Certification service on the hub and
performed CT image quality conformance assessment
calculations on CT phantom scans. Cloud-based phantom
analysis software was developed to perform a low-cost CT
image quality assessment using a specifically designed
phantom (ie, test object). This approach makes achieving
CT image quality conformance with the QIBA Small Lung
Nodule Profile possible from virtually any clinical imaging
site in the world.17,18 The purpose of this quality control step
is to ensure consistent image quality appropriate for the
defined context of use with lung cancer screening–related
quantitative assessment for imaging sites around the world.
The standardized assessment of CT lung imaging quality is
enabled using a dedicated, low-cost phantom (CTLX1) that
was developed for this purpose. The CTLX1 phantom
contains small, precision-made, geometric components to
assess thoracic CT imaging performance. A CT scan of the
CTLX1 phantom is typically acquired in approximately
5 minutes and then uploaded to the QIBA Phantom
Analysis Service, which rapidly analyzes the uploaded
phantom image using automated software to characterize
the quality of a CT scanner and acquisition process. The
results of the comprehensive QIBA CT image quality
analysis are sent back to the site within a few minutes using
an easy-to-interpret structured report indicating whether
the CT scanner and acquisition parameters were of suffi-
cient quality for quantitative assessment. If the image
quality was insufficient, then remediation measures are
suggested to the site to improve image quality. This analysis
has been performed at. 60 CT lung cancer screening sites
evaluating the use of the CTLX1 phantom, including
screening sites in Australia, England, Canada, China, Israel,
Italy, the Netherlands, Poland, Spain, Japan, and the
United States. The image quality data collected from the
analysis of CTLX1 phantom scans include CT scanner
image acquisition parameter settings such as milliampere,
peak kilovoltage, slice thickness, slice spacing, and re-
construction kernel, as well as fundamental image quality
characteristics achieved, including levels of edge en-
hancement, 3-dimensional (3D) resolution, 3D resolution
aspect ratio, CT linearity, noise, and 3D spatial warping.
Each of these fundamental image quality properties is
measured throughout the CT scanner field of view at 3
distances from isocenter (0, 100, and 200 mm) to ensure
that lung nodules present in the lung periphery, which is
common, can be accurately measured.
For proof-of-concept testing, the QIBA CT Small Lung
Nodule Profile Conformance automated phantom analysis
software was placed on SPOKE 1 running in northern
Virginia and used to run automated image quality analyses
on scans of the QIBA CT Small Lung Nodule Profile CTLX1
phantom. These tests confirmed that the fully automated
QIBA CT Small Lung Nodule Profile conformance certifi-
cation methods for CT image quality assessment will be
able to successfully run on future ELIC spokes (or hub)
running on the Amazon cloud.
A total of 5 live demonstrations were run using the ELIC
environment at 5 distinct time windows to evaluate the
ability of ELIC H&SE to perform useful quantitative imaging
computational experiments on large collections of globally
distributed CT lung cancer imaging cases without moving
data out of geographic regions. Each demonstration was
run for ELIC H&SE analyses performed with a central hub
server and 10 globally distributed spoke servers all running
on the AmazonWeb Services cloud. The prototype ELIC H&
SE Website22 allowed a user to launch a computational
experiment request on a specific set of data distributed
across any number of spokes, store the results, and display
an aggregated summary report of the results when the
analysis was complete.
In all, 3 pilot testing runs were performed. For these pilot
testing runs, quantitative lung volume analyses were
completed on 1,000 globally distributed CT lung cancer
screening data sets in , 25 minutes at 10 different ELIC
hosting sites from 4 continents. Figure 3 shows the main
user page available within the Website,22 which includes
IASLC-ELIC Initiative
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a listing of the available spokes, a place to specify the
launch of a quantitative experiment on the data located on
the spokes, and a list of pages showing the results obtained
from each experiment.
The developed H&SE software allows a hub server to make
quantitative CT imaging computational requests to a col-
lection of globally distributed spokes, each of which is
populated with de-identified CT lung images. The H&SE
software is set up so that each spoke performs a compu-
tational request and returns quantitative results back to the
hub. Figure 4 shows the results page from a representative
lung nodule measurement experiment (experiment 3)
performed on all the images at the 10 sites in the archive
with lung nodules (N = 62 × 10) in the ELIC H&SE. The
results reported were mean volume and standard deviation
for all the data sets analyzed. Figure 5 displays the detailed
FIG 3. The main user page available at www.iaslc-elic.org for the launch and review of quantitative lung imaging experiments on globally distributed
spokes.
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quantitative imaging results that were computed on CT lung
imaging cases on SPOKE 10 (Sao Paulo, Brazil) for the
same experiment as that shown in Figure 4 (experiment 3),
including the quantitative lung nodule volume values and 3
orthogonal reformat images with contours of the segmen-
tation results overlaid for each case.
Three presentations, including a live demonstration, were
given at IASLC’s 2018World Conference on Lung Cancer in
Toronto, Canada. In total, . 5 live demonstrations suc-
cessfully showed the simultaneous running of the CT lung
nodule algorithm on CT lung imaging cases distributed at
10 internationally distributed spoke sites.21
DISCUSSION
This initial proof-of-concept project demonstrated the po-
tential of the ELIC H&SE to provide a useful resource for
global quantitative lung imaging studies. This project used
FIG 4. Results page for a lung nodule measurement experiment performed in the ELIC Hub and Spoke Experiment.
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global cloud-computing resources, each populated with an
identical data set of 100 publicly available lung cancer
images. A central hub Website simultaneously distributed
2 open-source quantitative lung measurement algorithm
requests to the 10 globally distributed spoke sites. Using
publicly available CT lung images allowed the project to
achieve results quickly. The hub received and aggregated
all quantitative algorithm results from the spoke sites and
displayed the results on the hub Website. In addition, the
QIBA CT Small Lung Nodule Profile CT image quality
conformance testing service was successfully run on
a spoke to demonstrate that CT image quality monitoring
and optimization can be supported with the ELIC H&SE.
Although the developed proof-of-concept software imple-
mented a basic H&SE, the functionality represents a subset
of that which will be needed to fully realize the IASLC ELIC
H&SE vision. For example, the demonstration Website
supports only 1 user type; when mature, the ELIC H&SE
FIG 5. Detailed results for cases run on spoke 10 (Sao Paulo) for experiment 13.
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will support a variety of different roles and types of access
for clients, hub personnel, and spoke personnel. Future
versions of the ELIC H&SE will also provide higher levels of
security to prevent access or extraction of PI CT image data
as well as to prevent unauthorized use of client algorithms.
For these initial demonstrations, the client algorithms were
created as open-source projects and built on each spoke
into an executable application. However, a future ELIC H&
SE will likely also support the distribution of algorithms from
the hub. For example, the distribution of virtual containers
with executable applications embedded is being explored.
Future H&SE environmentswillalsoneedtoprovideadditional
functionalityandsupport forartificial intelligencedevelopment
and specifically, deep learning algorithm development and
testing. A fuller description of the methodology, governance,
data use provisions, scope, and other proposed policy ele-
ments are provided in the Data Supplement.
The ELIC H&SE prototype vehicle was developed with
IASLC seed funding to support feasibility testing and was
developed as an open-science and open-source research/
care environment to allow a broad range of collaborative
participation in achieving its CT imaging-related objectives.
Funding to sustain this large-scale international collabo-
rative effort will be dependent on the early lung cancer
research and innovation communities using ELIC in their
research to address important research and lung cancer
care issues. We expect many stakeholders, including
software developers, artificial intelligence companies, im-
aging researchers, diagnostic device developers, medical
imaging companies, government agencies, pharmaceuti-
cal developers, academic societies, and many other in-
novators, to be early users of the flexible capabilities of
ELIC. This service model is designed to allow a sustainable
path forward for this internationally accessible quantitative
imaging environment to emerge as a core resource for
improving the detection and management of early thoracic
disease.
The internationally federated ELIC hub-and-spoke system
has features such as robust data privacy provisions to
permit large-scale analyses of clinical CT images with
relevant associated data in a secure environment (ie, pri-
vacy protection that is under the control of the Trial/Study
PI), so that this resource could support the conduct of
clinical trials. This approach is intended to ensure local
governance control of the site PI, who can address the
specific data protection conditions at diverse international
locations.
In addition to prospective accumulation of individual new
screening cases, existing imaging collections will remain at
the local site where they were collected, so, again, the
resulting environment remains consistent with local regu-
lations without a privacy or data disclosure risk. An inherent
design feature of ELIC is to manage large numbers of
thoracic CT image screening registries. Therefore, control
of the processes for the users of the spokes and hub re-
quires a well-functioning informatics environment with
easy-to-setup and deployment tools that will enable rapid
screening care implementation as well as research by new
global lung cancer screening groups.
The power of ELIC relates to the accessibility of the cloud
and its remarkable cost efficiency.16 For image quality
processes, ELIC already uses machine vision and will soon
include artificial intelligence to ensure optimal and eco-
nomic image quality. This resource can greatly accelerate
radiomics and deep learning processes for medical images
and can be integrated with digital pathology and genomic
data. As the ELIC project continues to mature as a resource
to conduct analyses and study international collections of
high-quality thoracic CT images together with associated
biomedical data, there are a number of models through
which the pharmaceutical industry can be involved. For
example, drug company sponsors may host their own ELIC
spoke, on which they can collect quality-controlled CT
images associated with new innovative neoadjuvant stud-
ies, adjuvant or even chemoprevention clinical trials, and
associated clinical outcomes data. With each trial, the
sponsor can decide which image collections to acquire and
maintain as private versus aggregated in large public image
collections. In this fashion, aggregated image and data
collections could emerge as critical postmarketing research
and quality resources. Furthermore, access to large quality-
controlled CT screening images with clinical outcomes data
will provide the basis on which to construct the next
generation of algorithms to build models and tools, which
can function as clinical decision support. This is a rapidly
evolving area, and we are working to evolve ELIC in
alignment with new regulatory guidance relative to re-
sponsibly building international clinical decision support
tools for clinical care and research.23-25 Because thoracic
CT images from screening also contain information about
the presence of early coronary artery disease and chronic
obstructive disease, a high-quality international collection
of these images will be of growing public health value.26
In summary, the development and deployment of the ELIC
hub-and-spoke environment, together with fair and inter-
nationally developed governance policies, will establish, to
our knowledge for the first time, a large and efficient global
computing environment for the study of thoracic CT scans
obtained in the context of lung cancer screening. The use of
QIBA CT Small Lung Nodule Profile and the associated
phantoms and software tools will improve the quality of
global thoracic CT images aggregated for ELIC, ensuring
much more efficient image tool development. Not only will
these resources help accelerate lung imaging research and
the availability of thoroughly tested imaging tools, but the
data generated will provide insights to guide future rec-
ommendations for lung screening and for managing early
thoracic diseases.
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